On Monday, Global Brass and Copper Holdings Inc (NYSE:BRSS)’s shares inclined 2.61% to $18.51.
Global Brass and Copper Holdings, Inc. (BRSS) declared that, on August 4, 2015, its Board of Directors declared a quarterly cash dividend of $0.0375 per share on the Company’s common stock for the second quarter of 2015. The dividend will be paid on August 27, 2015 to stockholders of record on the close of business on August 17, 2015.
The declaration and payment of any future dividend will be subject to the discretion of the Board of Directors and will depend on a variety of factors, counting the Company’s financial condition and results of operations and contractual restrictions, such as the restrictive covenants contained in the Company’s indenture governing its 9.50% senior secured notes and in its credit agreement governing its asset-based revolving loan facility.
Global Brass and Copper Holdings, Inc. operates as a converter, fabricator, distributor, and processor of copper and brass products in the United States, the Asia Pacific, and Mexico. It operates in three segments: Olin Brass, Chase Brass, and A.J. Oster. The Olin Brass segment manufactures, fabricates, and converts copper and brass sheets, strips, foils, tubes, and fabricated components, in addition to rerolls and forms other alloys, such as stainless steel, carbon steel, and aluminum. Its products are used in munitions, automotive, coinage, building and housing, and electronics/electrical components end markets.
Pretium Resources Inc (NYSE:PVG)’s shares gained 2.88% to $5.35.
Pretium Resources Inc. (PVG) report the following highlights from the second quarter of 2015 and updates for its high-grade gold Brucejack Project in northern British Columbia.
Second Quarter 2015 Highlights and NoteworthyEvents
- On April 2, 2015, we declared that we had reached a comprehensive Cooperation and Benefits Agreement with the Nisga’a Nation in respect of our Brucejack Project (see news release dated April 2, 2015). This Agreement establishes a long-term, mutually-beneficial relationship between Pretivm and the Nisga’a Nation, who have rights and interests as defined by the Nisga’a Final Agreement in the Nass Area where portions of the Project are located.
- On May 13, 2015, we declared that Robert Quartermain had been designated as Chairman and Chief Executive Officer, Joseph Ovsenek was promoted to President, Michelle Romero was promoted to Vice President, Corporate and Kevin Torpy was promoted to General Manager - Brucejack Mine.
- On May 20, 2015, we declared a private placement of flow-through common shares of the Company, at a price of $8.75 per share. The private placement was accomplished on June 8, 2015 and a total of 800,000 flow-through shares were issued, for total gross proceeds of about $7,000,000. The proceeds from the private placement will be used to fund grass-roots exploration with an airborne geophysical program and a surface drill program targeting geophysical anomalies east of the Brucejack Project.
Pretium Resources Inc. acquires, explores, and develops precious metal resource properties in the Americas. Its mineral interests comprise of gold/copper/silver exploration projects. The company primarily holds a 100% interest in the Brucejack project, which comprises of about 11 mineral claims covering an area of 3,199.28 hectares located in Northwestern British Colombia. It also holds a 100% interest in the Snowfield project that comprises one mineral claim with an area of about 1,267.43 hectares. Pretium Resources Inc. was incorporated in 2010 and is headquartered in Vancouver, Canada.
At the end of Monday’s trade, Expedia Inc (NASDAQ:EXPE)‘s shares surged 1.12% to $123.01.
Expedia Inc (EXPE) declared the results of a collaborative study to determine how travel and romance intersect for Americans. The 2015 Foreign Affairs Study was commissioned by Expedia® and Tinder and conducted by GfK, an independent global market research company.
GfK asked 1,000 Americans a range of questions about travel and romance, counting how early in a relationship they would consider taking an overnight vacation, which destination features they would prioritize on their first trip away, how willing they would be to vacation with a partner’s parents and where the most attractive dating populations reside.
The full Expedia/Tinder 2015 Foreign Affairs Study can be found here on the Expedia® Viewfinder blog. In addition to this, Expedia and Tinder also launched a Match Made in Travel game that allows users to swipe right on their favorite locations and get paired with their ideal destination match. Check out the game here.
Expedia, Inc., together with its auxiliaries, operates as an online travel company in the United States and internationally. The company operates in two segments, Leisure and Egencia. It provides travel products and services to leisure and corporate travelers, offline retail travel agents, and travel service providers through a portfolio of brands, counting Expedia.com, Hotels.com, Hotwire.com, Classic Vacations, Travelocity, Expedia Local Expert, Egencia, Expedia CruiseShipCenters, eLong, and Venere.com, in addition to trivago, CarRentals.com, Wotif.com, lastminute.com.au, travel.com.au, Asia Web Direct, LateStays.com, GoDo.com.au, and Arnold Travel Technology.
ABIOMED, Inc. (NASDAQ:ABMD), ended its Monday’s trading session with 2.43% gain, and closed at $106.45.
Abiomed, Inc. (ABMD), declared that it has presented U.S Food & Drug Administration (FDA) pre-market approval (PMA) supplemental submissions requesting to expand Impella® 2.5 PMA approval to all of the Impella family of devices (Impella 2.5, Impella CP® and Impella 5.0/LD). The submissions are for a set of indications related to the use of the Impella devices in patients suffering cardiogenic shock following acute myocardial infarction or cardiac surgery. A request for a longer duration of support is also comprised of.
These submissions are projected as a supplement to the Impella 2.5 PMA approval for high risk percutaneous coronary intervention (PCI) received on March 23, 2015, and comprise analysis on 415 patients from the FDA study RECOVER 1 and the U.S. Impella registry, and a relevant Impella literature review that references 692 patients in 17 clinical studies. Additionally, over 24,000 Impella patients supported by Impella devices were reviewed in a safety analysis offered using the FDA/Medical Device Reporting (MDR) database. Through its review of the supplemental submission, the FDA will ultimately render a decision concerning the safety and efficacy of the Impella CP and the Impella 5.0 in the applied-for patient populations.
ABIOMED, Inc. researches, develops, and sells medical devices in circulatory support and continuum of care in heart recovery to acute heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
